New combo therapy targets Tough-to-Treat myeloma
NCT ID NCT06550895
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study is testing a combination of two treatments—cilta-cel (a cell therapy) and talquetamab (a drug)—in 11 people with high-risk multiple myeloma that has not responded to prior therapies. The main goal is to check safety and side effects. Researchers will also look at whether the combination helps shrink or control the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ciltacabtagene autoleucel (a cell therapy) and talquetamab (a drug)
What this could lead to
If it works, this could point toward a new treatment option for people with high-risk multiple myeloma who have not responded to other therapies.
What could go wrong
This is a very early, small phase 2 safety study with only 11 participants. The combination may cause serious side effects, and it is not yet known if it will effectively control the disease long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Austin Hospital
Heidelberg, 3084, Australia
-
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Norton Cancer Institute
Louisville, Kentucky, 40207, United States
-
Peter MacCallum Cancer Centre
Melbourne, 3000, Australia
-
Royal Prince Alfred Hospital
Camperdown, 2050, Australia
-
The Alfred Hospital
Melbourne, 3004, Australia
-
University of Iowa Hospital and Clinics
Iowa City, Iowa, 52242, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States